CSL Limited ( ASX:CSL ) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to ...

Csl Ltd ( ($CSLLY) ) has released its Q2 earnings. Here is a breakdown of the information Csl Ltd presented to its investors.

There were positives and negatives in the company's first half performance. The post CSL shares push higher despite 'mixed ...

This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

CSL Vifor Thank you for standing by and welcome to the CSL Limited Half Year Financial Results. All participants are in a listen-only mode. There will be a presentation followed by a question-and ...

Today's Elliott Wave analysis provides an update on the Australian Stock Exchange (ASX) focusing on CSL LIMITED (CSL). There is significant upside potential in the third wave of ASX:CSL. This analysis ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

These three premier ASX healthcare stocks just reported half-yearly earnings – and each saw its share price dip…So, is now the time to buy?

(RTTNews) - CSL Limited (CSL.AX) Thursday, announced that the European Commission has approved ANDEMBRY, a once-monthly treatment for hereditary angioedema or HAE in patients aged 12 and older.

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...